Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Hansoh Acquires China Rights to Novel Synexis Antifungal

publication date: Feb 17, 2021

Hansoh Pharma of Jiangsu Province acquired China rights to a late-state anti-fungal candidate for difficult-to-treat and drug-resistant infections from Synexis, a New Jersey biotech. Hansoh will make a $10 million upfront payment to Synexis, plus unspecified milestones and royalties. Ibrexafungerp is a first-in-class, broad-spectrum triterpenoid antifungal agent with both IV and oral formulations. It is currently under US NDA review to treat vaginal yeast infections and in late-stage development for other indications including fungal infections in hospitalized patients. More details....

Stock Symbols: (HK: 3692) (NSDQ: SCYX)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital